Goodwin-Led Biotech Startup Launches Plans For $101M IPO
PepGen Inc. set a price range on Monday for an estimated $101 million initial public offering that will fund therapies for neuromuscular diseases, guided by Goodwin Procter LLP and underwriters counsel...To view the full article, register now.
Already a subscriber? Click here to view full article